Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
- 15 June 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (12), 3117-3125
- https://doi.org/10.1200/jco.2001.19.12.3117
Abstract
PURPOSE: To develop a combination of pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA) and docetaxel (Taxotere; Aventis Pharmaceutical, Parsipanny, NJ) that can be safely used for the treatment of advanced breast cancer. PATIENTS AND METHODS: Forty-one patients with locally advanced (n = 10) or metastatic (n = 31) breast cancer received Doxil (30-, 40-, or 45-mg/m2 intravenous [IV] infusion over 30 to 60 minutes), followed 1 hour later by docetaxel (60 or 75 mg/m2 by IV infusion over 1 hour) in cohorts of three to six patients. Dose-limiting toxicity (DLT) was defined as febrile neutropenia, prolonged neutropenia, or grade 3 to 4 nonhematologic toxicity that occurred during cycle 1. RESULTS: In conjunction with docetaxel 75 mg/m2 every 4 weeks, the MTD of Doxil was 30 mg/m2 and required granulocyte colony-stimulating factor (G-CSF) to prevent febrile neutropenia. Without G-CSF, the MTD was docetaxel 60 mg/m2 and Doxil 30 mg/m2 every 3 weeks; only 1 (7%) out of 15 patients treated at this dose level had cycle 1 DLT. Infusion reactions were common with Doxil with the recommended infusion schedule during the first cycle (55%) but were reduced with a modified schedule (7%). There was no clinically significant cardiac toxicity. Objective response occurred in eight of nine assessable patients with stage III disease and in 16 (52%) of 31 patients (95% confidence interval, 34% to 70%) with stage IV disease. CONCLUSION: The recommended dose and schedule of this combination for further evaluation is Doxil 30 mg/m2 and docetaxel 60 mg/m2 given every 3 weeks without G-CSF. When used with G-CSF, it is Doxil 30 mg/m2 and docetaxel 75 mg/m2 every 4 weeks.Keywords
This publication has 28 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Taxanes for Breast Cancer: An Evidence-Based Review of Randomized Phase II and Phase III TrialsClinical Breast Cancer, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- 650: Taxotere™ (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)European Journal Of Cancer, 1997
- Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacyJournal of Neurosurgery, 1995
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Cytoskeletal agents inhibit motility and adherence of human tumor cellsKidney International, 1993
- Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomesInternational Journal of Cancer, 1992
- Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscopeJournal of Molecular Biology, 1964
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958